| Trial ID # | NCT01802749; MITO16B-MaNGO OV2B |
| Phase | III |
| Drug Class | Angiogenesis Inhibitors: VEGF |
| Drug Name | Bevacizumab |
| Alternate Drug Names | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin |
| Drugs in Trial | Carboplatin, Liposomal doxorubicin, Paclitaxel, Bevacizumab, Gemcitabine |
| Eligible Participant | Platinum sensitive ovarian cancer after first-line treatment incl. bevacizumab (recurrence or progression either during or after bevacizumab as maintenance) |
| Patients Enrolled | 406 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Randomized |
| Endpoints | ORR, PFS, OS, evaluated per RECIST |
| Efficacy | CarboPt+Pac+Bev vs CarboPt+Pac: ORR: 74.6 (20CR, 77PR) vs 65.7% (9CR, 85PR) |
| Clinically Significant Adverse Events | CarboPt+Pac+Bev vs CarboPt+Pac: |
| Conclusion | Rechallenge with bevacizumab in combination with platinum-based doublets is associated with a significantly prolonged PFS |
| Reference | Pignata S et al. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trialMITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol (2018) 36 (suppl; abstr 5506) Pignata S et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol (2021) 22(2):267-276 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.